Non-invasive fractional flow reserve tech developer CathWorks said yesterday it won a new CPT code covering its 3D FFRangio non-invasive fractional flow reserve analysis technology.
The Israel-based company’s 3D FFRangio technology is now reimbursable when used for the real-time review of possible atherosclerotic stenosis during coronary angiography interventions.
The FFRangio tech is designed as a non-invasive FFR platform that provides multi-vessel physiologic measurements, CathWorks said.
“CPT code 0523T approval is a very important step for our company and the market. The CPT code decision also reflects the long-term clinical importance of objective FFR-based PCI decision-making. Creating a long-term reimbursement solution to support intraprocedural FFRangio will enable physicians, patients, and payers to realize the proven clinical and economic benefits of FFR on an every-case basis,” CEO Jim Corbett said in a press release.
Last October, CathWorks said it closed a $15.8 million Series B round of financing to support its real-time digital platform designed to determine FFR in cath labs.
Intuitive Surgical enjoyed a nearly two-decade monopoly in the robot-assisted surgery space. At DeviceTalks West, we'll delve into that history as longtime CEO Gary Guthart tells us how he got his start in medtech, how Intuitive came to enjoy such a commanding lead and what the future holds for medical robotics.
Use code GUTHART to save an additional 10%.